InsidersTradesSigma
Total declarations
Company
▲ Purchases (21 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
21
Disclosed sells
0
T+90 hit rate
27%
T+90 mean return
-2.5%
Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Freeman Kevin d, Director. Officer active across 1 company, notably Galectin Therapeutics INC. Aggregated, 22 filings have been published. Breakdown: 21 buys · 0 sell. Total volume traded: €204k. Activity tracked since 23 September 2021. The latest transaction was filed on 23 December 2025 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Freeman Kevin d
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations22 total
5,500 shares@ US$3.5488.1% of flowCommon StockSEC:0001133416-25-000080:0
Canonical exit: 23 Mar 2026 (T+90)
5,500 shares@ US$3.5488.1% of flowCommon StockSEC:0001133416-25-000075:0
Canonical exit: 23 Mar 2026 (T+90)
5,500 shares@ US$3.5488.1% of flowCommon StockSEC:0001133416-25-000081:0
Canonical exit: 23 Mar 2026 (T+90)
5,000 shares@ US$2.8998.1% of flowCommon StockSEC:0001133416-25-000033:0
Canonical exit: 15 Oct 2025 (T+90)
10,000 shares@ US$0.81343.6% of flowCommon StockSEC:0001133416-24-000062:0
Canonical exit: 24 Mar 2025 (T+90)
1,300 shares@ US$2.641.4% of flowCommon StockSEC:0001133416-24-000058:0
Canonical exit: 15 Jan 2025 (T+90)
5,000 shares@ US$2.705.7% of flowCommon StockSEC:0001133416-24-000056:0
Canonical exit: 14 Jan 2025 (T+90)
2,500 shares@ US$2.37992.5% of flowCommon StockSEC:0001133416-24-000044:0
Canonical exit: 18 Sept 2024 (T+90)
2,500 shares@ US$2.983.2% of flowCommon StockSEC:0001133416-24-000038:0
Canonical exit: 21 Jul 2024 (T+90)
2,063 shares0Common StockSEC:0001133416-24-000036:0
10,000 shares@ US$1.416.5% of flowCommon StockSEC:0001133416-22-000093:0
Canonical exit: 26 Jan 2023 (T+90)
5,000 shares@ US$1.32993.9% of flowCommon StockSEC:0001133416-22-000063:0
Canonical exit: 17 Aug 2022 (T+90)
5,000 shares@ US$1.714.9% of flowCommon StockSEC:0001133416-22-000057:0
Canonical exit: 17 Jul 2022 (T+90)
5,000 shares@ US$1.96120.0029% mcap5.1% of flowCommon StockSEC:0001133416-22-000010:0
Canonical exit: 19 Apr 2022 (T+90)
5,000 shares@ US$1.96125.3% of flowCommon StockSEC:0001133416-22-000008:0
Canonical exit: 19 Apr 2022 (T+90)
5,000 shares@ US$2.286.2% of flowCommon StockSEC:0001133416-21-000025:0
Canonical exit: 6 Mar 2022 (T+90)
5,000 shares@ US$2.286.2% of flowCommon StockSEC:0001133416-21-000027:0
Canonical exit: 15 Mar 2022 (T+90)
5,000 shares@ US$2.346.4% of flowCommon StockSEC:0001133416-21-000023:0
Canonical exit: 6 Mar 2022 (T+90)
2,000 shares@ US$3.173.3% of flowCommon StockSEC:0001133416-21-000017:0
Canonical exit: 27 Jan 2022 (T+90)
2,000 shares@ US$3.193.4% of flowCommon StockSEC:0001133416-21-000013:0
Canonical exit: 19 Jan 2022 (T+90)
3,000 shares@ US$3.36895.4% of flowCommon StockSEC:0001133416-21-000011:0
Canonical exit: 17 Jan 2022 (T+90)
3,000 shares@ US$3.8776.1% of flowCommon StockSEC:0001140361-21-032248:0
Canonical exit: 22 Dec 2021 (T+90)
22 of 22 declarations
About Freeman Kevin d
Kevin D. Freeman is Administrateur at Galectin Therapeutics INC (XNAS). He has 22 filings in total, and in the sampled recent filings the activity consists only of purchases for EUR 203937 between 2021-09-23 and 2025-12-23.
